<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70179">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192164</url>
  </required_header>
  <id_info>
    <org_study_id>B1801365</org_study_id>
    <nct_id>NCT02192164</nct_id>
  </id_info>
  <brief_title>Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis</brief_title>
  <official_title>Non-interventional Study Of The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot observational study to describe the relationship between the smoking status of a
      psoriatic individual and the success of etanercept therapy in psoriasis treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      non-interventional study There is no sampling
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Psoriasis Assessment And Severity Index from baseline to 12 weeks and 24 weeks</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>Commonly used measurement of psoriasis severity by measuring induration, desquamation and erythema of the skin combined with body surface are affected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking Habit Questionnaire</measure>
    <time_frame>baseline</time_frame>
    <description>Short questionnaire aboout current and past smoking habits of the patients</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">126</enrollment>
  <condition>Plaque Psoriasis</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>smoking questionnaire</intervention_name>
    <description>patients fill in a smoking questionnaire about their smoking habits</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        etanercept treated plaque psoriasis patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by
        the subjects medical history, and confirmation of the diagnosis through physical
        examination by the investigator Patients who are scheduled by their dermatologist to
        initiate treatment with Etanercept

        Exclusion Criteria:

        Previous or current treatment with antipsoriatic biologic drugs, such as etanercept,
        infliximab, adalimumab, ustekinumab, alefacept, efalizumab Chronic or acute infections
        requiring intravenous or oral anti-infectives within 14 days prior to the Baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>H-1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum/Bor- es Nemikortani Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház</name>
      <address>
        <city>Kaposvár</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Onkormanyzat Korhaza Szegedi Tudomanyegyetem AOK Oktato Korhaza</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Korhaz-Rendelointezet</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem, Br-, Nemikortani es Onkodermatologiai Klinika</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas Megyei Markusovszky Korhaz/Borgyogyaszati Osztaly</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801365&amp;StudyName=Non-interventional%20Study%20of%20the%20Effect%20of%20Smoking%20Status%20of%20the%20Patient%20on%20the%20Success%20of%20Etanercept%20Therapy%20in%20Psoriasis%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 8, 2016</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque psoriasis</keyword>
  <keyword>smoking</keyword>
  <keyword>etanercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
